Softwr

Research · head to head

Dotmatics vs LatchBio

Dotmatics logo

Dotmatics

Research

Research informatics group behind GraphPad Prism, SnapGene, Geneious and LabArchives, now owned by Siemens

From
On request
Rated
-
Full reviewWebsite
LatchBio logo

LatchBio

AI

AI agents that run bioinformatics analyses, from a company that pivoted from workflow hosting

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Dotmatics the portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.; LatchBio the company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.
  • They diverge on capability: Dotmatics covers Dotmatics platform, LatchBio covers Agent driven analysis.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Dotmatics and LatchBio actually diverge.

Attributes where Dotmatics and LatchBio differ
AttributeDotmaticsLatchBio
PlatformsWeb, Windows, macOS, On-premiseWeb
CategoryResearchAI

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Dotmatics

  • Dotmatics platform
  • GraphPad Prism
  • SnapGene
  • Geneious Prime and Biologics
  • LabArchives
  • Flow cytometry tools
  • Protein Metrics
  • Siemens ownership

Only in LatchBio

  • Agent driven analysis
  • Multi assay support
  • Published benchmarks
  • White labelled portals
  • Common file format handling
  • Managed compute

What people use each for

The jobs each tool is most often brought in to do.

Dotmatics

  • A pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layernot LatchBio
  • A biotech that already owns Prism, SnapGene and Geneious separately and wants to understand what a group contract would covernot LatchBio
  • A university licensing LabArchives across departments as an institutional electronic lab notebooknot LatchBio
  • A biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement routenot LatchBio

LatchBio

  • A small biotech with sequencing data and no bioinformatician who needs a first pass differential expression or cell type annotation quicklynot Dotmatics
  • An assay or kit vendor that wants to give customers an analysis portal under its own branding rather than shipping raw filesnot Dotmatics
  • A wet lab scientist who wants to explore a dataset interactively before commissioning a formal analysis from a core facilitynot Dotmatics
  • A research group benchmarking agent produced analyses against its own established pipeline to decide how much routine work can be delegatednot Dotmatics

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Dotmatics

  • The portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.
  • The Siemens acquisition completed in July 2025 with stated revenue synergy targets, which usually translates into pressure to move individually bought desktop licences into larger platform agreements, and small buyers of a single Prism or SnapGene seat should expect that pressure at renewal.
  • Nothing about the enterprise platform is publicly priced, and even the individual applications are increasingly moved to subscription, so total cost across a research group is hard to establish before negotiation.
  • Each acquired product retains its own licence terms, support channel and release cycle, so an organisation using four Dotmatics brands manages four different renewal dates, entitlement models and support experiences.
  • Enterprise deployments require data migration and configuration services, and validated instances for regulated use add both cost and an ongoing customer revalidation duty after each release, so the informatics platform is a programme rather than a purchase.

LatchBio

  • The company has pivoted from hosted bioinformatics workflows to AI agents, so organisations that adopted the earlier SDK and workflow product are now on a line that is no longer the strategic focus.
  • Agent generated analysis code has to be validated by someone who could have written it, which inverts the value proposition for the small labs that most need it and cannot check the output.
  • No pricing is published, so the cost of routine agent analysis at team scale cannot be estimated without contacting sales, and compute billed through the platform makes the bill usage dependent.
  • Regulated use is a poor fit: an agent that writes non deterministic analysis code is difficult to validate under GxP, so this is a research tool rather than something that will sit in a regulated diagnostic or submission workflow.
  • The vendor publishes its own benchmarks, which is more than most competitors do, but self reported benchmarks on selected datasets are not a substitute for testing the agent on your own data before committing.

Pricing, plan by plan

Dotmatics

On request
  • Dotmatics platform$undefined/year
    • Enterprise informatics platform priced per user per year on quotation
    • Chemistry and biology registration, assay data and ELN modules scoped separately
    • Implementation and data migration services quoted as a separate programme

LatchBio

On request
  • LatchBio Platform$undefined/year
    • Quoted through a sales process
    • Interactive sandbox available for trying the agent before contracting
    • Enterprise and white labelled portal deployments priced separately

Which should you pick?

Choose Dotmatics if

  • You need dotmatics platform.
  • You work on Web, Windows, macOS, On-premise.
  • You also want graphpad prism.
Dotmatics review

Choose LatchBio if

  • You need agent driven analysis.
  • You also want multi assay support.
LatchBio review

Questions people ask

Is Dotmatics or LatchBio better?
Neither clearly leads. Dotmatics starts at On request and LatchBio at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Dotmatics or LatchBio?
Dotmatics starts at On request and LatchBio at On request.
Does Dotmatics or LatchBio run on more platforms?
Dotmatics runs on Web, Windows, macOS, On-premise. LatchBio runs on Web.
What is Dotmatics best used for?
Dotmatics is most often used for a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer, a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover, a university licensing labarchives across departments as an institutional electronic lab notebook, a biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement route. Of those, a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer and a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover are not what LatchBio is typically brought in for.
What can Dotmatics do that LatchBio cannot?
Dotmatics covers Dotmatics platform, GraphPad Prism, SnapGene, Geneious Prime and Biologics. LatchBio covers Agent driven analysis, Multi assay support, Published benchmarks, White labelled portals.

Answered from the vendors’ own pages

Dotmatics: Who owns Dotmatics?

Siemens, which completed a 5.1 billion dollar acquisition on 1 July 2025. Dotmatics now sits inside Siemens Digital Industries Software.

LatchBio: Is LatchBio still selling the original workflow platform?

The company is now led by agent.bio and its agent products. Buyers evaluating the older Python SDK workflow platform should confirm current support directly.

Dotmatics: Is GraphPad Prism a Dotmatics product?

Yes. So are SnapGene, Geneious, LabArchives, FCS Express, OMIQ, Protein Metrics, SoftGenetics and nQuery.

LatchBio: Can I try it before buying?

Yes. There is an interactive sandbox where you can upload data and run the agent before entering a sales conversation.

Dotmatics: Do the products work together?

To varying degrees. They were acquired separately and integration across the portfolio is uneven, so verify the specific pair you care about before assuming it.

LatchBio: Is it suitable for regulated work?

Not really. Non deterministic agent generated code is hard to validate under GxP, so treat it as a research and exploration tool.

Dotmatics: Is enterprise pricing published?

No. The informatics platform is quoted per user per year with modules and services scoped separately.

LatchBio: What data types does it handle?

Single cell RNA sequencing, spatial transcriptomics, epigenomics, proteomics and pharmacology data, ingesting FastQ, H5AD and spreadsheet formats.

Share

Related pages

More on Dotmatics

More on LatchBio

Keep looking

Other head to heads